Ohtuvayre (ensifentrine), a drug approved in 2024 to treat chronic obstructive pulmonary disorder (COPD), is receiving high marks from doctors and patients. Ohtuvayre is the first new inhaled COPD ...
Asthma and COPD Drugs Market is expected to reach US$ 82.2 Billion by 2036, driven by Advancements in Drug Discovery and ...
There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease (COPD), according to real-world ...
Inhalers and nebulizers are necessary when managing chronic obstructive pulmonary disease (COPD). Both are designed to deliver medication directly to the lungs, which helps in reducing symptoms, ...
Please provide your email address to receive an email when new articles are posted on . Less than 40% of the studied veteran cohort were adherent to their inhaled COPD medications. Adherence was found ...
6don MSN
Why do most people mistake COPD for asthma? Pulmonologist explains why that delay can be deadly
Misunderstanding COPD and asthma can be risky. Recognising the difference in the condition, treatment options, and the need for early intervention is important.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback